Lecanemab in Practice: Real‐World Data from a 6‐Month Follow‐Up in Early Alzheimer’s Disease

Abstract

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a significant impact on patients and healthcare systems. Lecanemab, a monoclonal antibody targeting amyloid beta, has recently been approved for early‐stage AD, offering potential for disease modification.

The paper